Literature DB >> 7585606

Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1.

S M Hewitt1, S Hamada, T J McDonnell, F J Rauscher, G F Saunders.   

Abstract

The Wilms' tumor gene WT1 functions as a tumor suppressor gene, repressing transcription of several growth factors and growth factor receptors. The bcl-2 and c-myc proto-oncogenes are essential for regulation of apoptosis and cell proliferation with roles in development and oncogenesis. We found that WT1 can repress transcription of both the bcl-2 and c-myc promoters. This suggests that WT1 regulates bcl-2 and c-myc during renal development, and the loss of functional WT1 results in deregulation of bcl-2 and c-myc, contributing to tumor formation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7585606

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  59 in total

1.  Aiolos transcription factor controls cell death in T cells by regulating Bcl-2 expression and its cellular localization.

Authors:  F Romero; C Martínez-A; J Camonis; A Rebollo
Journal:  EMBO J       Date:  1999-06-15       Impact factor: 11.598

2.  Apoptosis: A Current Molecular Analysis.

Authors:  Dean G Tang; Arthur T Porter
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

Review 3.  The possible role and application of WT1 in human leukemia.

Authors:  Z Chen
Journal:  Int J Hematol       Date:  2001-01       Impact factor: 2.490

Review 4.  Wilms' tumor gene WT1: its oncogenic function and clinical application.

Authors:  H Sugiyama
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

Review 5.  Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials.

Authors:  Ann Van Driessche; Zwi N Berneman; Viggo F I Van Tendeloo
Journal:  Oncologist       Date:  2012-01-30

6.  Opposite regulation of estrogen receptor-α and its variant ER-α36 by the Wilms' tumor suppressor WT1.

Authors:  Lianguo Kang; Lei Wang; Zhao-Yi Wang
Journal:  Oncol Lett       Date:  2011-01-21       Impact factor: 2.967

Review 7.  Candidate genes and potential targets for therapeutics in Wilms' tumour.

Authors:  Christopher Blackmore; Max J Coppes; Aru Narendran
Journal:  Clin Transl Oncol       Date:  2010-09       Impact factor: 3.405

8.  CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors.

Authors:  Chi-Ming Li; Connie E Kim; Adam A Margolin; Meirong Guo; Jimmy Zhu; Jacqueline M Mason; Terrence W Hensle; Vundavalli V V S Murty; Paul E Grundy; Eric R Fearon; Vivette D'Agati; Jonathan D Licht; Benjamin Tycko
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

9.  Differential sensitization of two human colon cancer cell lines to the antitumor effects of irinotecan combined with 5-aza-2'-deoxycytidine.

Authors:  Shuko Hakata; Jun Terashima; Yu Shimoyama; Kouji Okada; Shiho Fujioka; Erika Ito; Wataru Habano; Shogo Ozawa
Journal:  Oncol Lett       Date:  2018-01-26       Impact factor: 2.967

Review 10.  Strategies to reduce relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia.

Authors:  Raya Mawad; Jack M Lionberger; John M Pagel
Journal:  Curr Hematol Malig Rep       Date:  2013-06       Impact factor: 3.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.